These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 35964291)
1. Authors' reply to: 'Generalized pustular figurate erythema first report in two COVID-19 patients on hydroxychloroquine'. Bertello M; Rubegni G; Rubegni P; Tognetti L J Eur Acad Dermatol Venereol; 2023 Feb; 37(2):e233-e235. PubMed ID: 35964291 [No Abstract] [Full Text] [Related]
2. Generalized pustular figurate erythema first report in two COVID-19 patients on hydroxychloroquine. Abadías-Granado I; Palma-Ruiz AM; Cerro PA; Morales-Callaghan AM; Gómez-Mateo MC; Gilaberte Y; Schwartz RA J Eur Acad Dermatol Venereol; 2021 Jan; 35(1):e5-e7. PubMed ID: 32870539 [No Abstract] [Full Text] [Related]
3. Comment on "Generalized pustular figurate erythema: A newly delineated severe cutaneous drug reaction linked with hydroxychloroquine": Report of a COVID-19 patient with particular findings. Suarez-Valle A; Fernandez-Nieto D; Melian-Olivera A; Dominguez-Santas M; Diaz-Guimaraens B; Garcia Del Real CM; Jimenez-Cauhe J Dermatol Ther; 2020 Nov; 33(6):e13852. PubMed ID: 32543708 [No Abstract] [Full Text] [Related]
4. Generalized Pustular Figurate Erythema in Patients with COVID-19 Treated with Hydroxychloroquine: A Systematic Review. Al Muqarrab F; Schwartz RA; Almohssen AA Acta Dermatovenerol Croat; 2022 Dec; 30(4):227-236. PubMed ID: 36919389 [TBL] [Abstract][Full Text] [Related]
5. Generalized pustular figurate erythema: A newly delineated severe cutaneous drug reaction linked with hydroxychloroquine. Schwartz RA; Janniger CK Dermatol Ther; 2020 May; 33(3):e13380. PubMed ID: 32253799 [TBL] [Abstract][Full Text] [Related]
6. Acute generalized exanthematous pustulosis with erythema multiforme-like lesions induced by Hydroxychloroquine in a woman with coronavirus disease 2019 (COVID-19). Robustelli Test E; Vezzoli P; Carugno A; Raponi F; Gianatti A; Rongioletti F; Sena P J Eur Acad Dermatol Venereol; 2020 Sep; 34(9):e457-e459. PubMed ID: 32386448 [No Abstract] [Full Text] [Related]
7. Hydroxychloroquine-induced erythema multiforme in a patient with COVID-19. Monte Serrano J; Cruañes Monferrer J; García-García M; García-Gil MF Med Clin (Barc); 2020 Sep; 155(5):231. PubMed ID: 32522372 [No Abstract] [Full Text] [Related]
8. Acute generalized exanthematous pustulosis and Stevens-Johnson syndrome overlap due to hydroxychloroquine: a case report. Coleman I; Ruiz G; Brahmbhatt S; Ackerman L J Med Case Rep; 2020 Nov; 14(1):210. PubMed ID: 33138853 [TBL] [Abstract][Full Text] [Related]
10. Response to: 'COVID-19 among Malaysian patients with systemic lupus erythematosus on hydroxychloroquine' by Teh Mathian A; Amoura Z Ann Rheum Dis; 2021 May; 80(5):e70. PubMed ID: 32737109 [No Abstract] [Full Text] [Related]
11. Acute generalized exanthematous pustulosis induced by hydroxychloroquine prescribed for COVID-19. Delaleu J; Deniau B; Battistella M; de Masson A; Bensaid B; Jachiet M; Lazaridou I; Bagot M; Bouaziz JD; J Allergy Clin Immunol Pract; 2020 Sep; 8(8):2777-2779.e1. PubMed ID: 32525093 [No Abstract] [Full Text] [Related]
12. Facts, not Fear: Safety of Hydroxychloroquine. Kuraitis D; Murina A Am J Med Sci; 2020 Aug; 360(2):199-200. PubMed ID: 32560964 [No Abstract] [Full Text] [Related]
13. Erythema annulare centrifugum due to hydroxychloroquine sulfate and chloroquine sulfate. Ashurst PJ Arch Dermatol; 1967 Jan; 95(1):37-9. PubMed ID: 6016304 [No Abstract] [Full Text] [Related]
14. Response to: 'Clinical course of COVID-19 in patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine' by Carbillon Konig MF; Gianfrancesco M; Yazdany J; Robinson PC Ann Rheum Dis; 2021 Apr; 80(4):e55. PubMed ID: 32475834 [No Abstract] [Full Text] [Related]
15. Correspondence on 'Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus under long-term treatment with hydroxychloroquine'. Nikpour M; Teh B; Wicks IP; Pellegrini M Ann Rheum Dis; 2021 Mar; 80(3):e33. PubMed ID: 32471898 [No Abstract] [Full Text] [Related]
17. Acute generalized exanthematous pustulosis induced by hydroxychloroquine: a case with atypical clinical presentation. Duman H; Topal IO; Kocaturk E; Cure K; Mansuroglu I An Bras Dermatol; 2017; 92(3):404-406. PubMed ID: 29186260 [TBL] [Abstract][Full Text] [Related]
18. Why the article that led to the widespread use of hydroxychloroquine in COVID-19 should be retracted. Barraud D; Besançon L; Bik EM; Billy E; Clarot F; Frank F; Guihur A; Hajage D; Lacombe K; Maisonneuve H; Molimard M; Mulot M; Samuel A Therapie; 2023; 78(4):437-440. PubMed ID: 37321944 [No Abstract] [Full Text] [Related]
19. Acute generalized exanthematous pustulosis after COVID-19 treatment with hydroxychloroquine. Litaiem N; Hajlaoui K; Karray M; Slouma M; Zeglaoui F Dermatol Ther; 2020 Jul; 33(4):e13565. PubMed ID: 32401410 [No Abstract] [Full Text] [Related]
20. Antirheumatic drugs, B cell depletion and critical COVID-19: correspondence on 'Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine' by Mathian Notz Q; Meybohm P; Kranke P; Weismann D; Lotz C; Schmalzing M Ann Rheum Dis; 2022 Nov; 81(11):e216. PubMed ID: 32859609 [No Abstract] [Full Text] [Related] [Next] [New Search]